Adcendo: $135 Million (Series B) Raised For Developing Treatments To Address Underserved Cancers
By Amit Chowdhry ● Dec 2, 2024
Adcendo, a biotech company focused on developing first-in-class ADCs for treating cancers with a high unmet medical need, announced the closing of an oversubscribed $135 million Series B financing round. The funding was led by TCGX, with participation from new investors TPG Life Sciences Innovations, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, as well as all existing investors, including RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital.